Carcinoma of Unknown Primary — Trials

Carcinoma of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,151
Recruiting: 2,258
Ph III recruiting: 267
Growth YoY: +13.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,893)

clinicaltrialsPublishedShowing 201–250 of 1,045 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	active not recruiting	Phase 1	50	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT04427293	Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)	active not recruiting	Phase 1	12	University of Illinois at ChicagoOTHER	1	Aug 28, 2026